1. Scrip
  2. >>Therapy Areas
  3. >>Dermatological

Better apart: a la Abbott, Baxter split in two

 
• By Sukaina Virji

Baxter International is splitting into two companies – one focused on biopharmaceuticals and the other on medical products. In much the same way and citing the same "compelling rationale" that Abbott did just over two years, chairman and CEO Robert Parkinson says the two businesses have unique growth prospects, investment requirements and risk profiles that would be best served separately (scripintelligence.com, 19 October 2011).

Baxter International is splitting into two companies – one focused on biopharmaceuticals and the other on medical products. In much the same way and citing the same "compelling rationale" that Abbott did just over two years, chairman and CEO Robert Parkinson says the two businesses have unique growth prospects, investment requirements and risk profiles that would be best served separately (scripintelligence.com, 19 October 2011).

The markets agreed, sending Baxter's share price up by 9% in pre-market trading on Nasdaq over the previous day's close.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Dermatological

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

InflaRx Stock Sinks As Vilobelimab Fails Phase III Skin Trial

 
• By Kevin Grogan

A study of the German biotech's intravenous complement factor C5a antibody for pyoderma gangrenosum was stopped for futility.

Leo Roars To A Profit In Q1 As Adbry Grows In US

 
• By Kevin Grogan

The Danish firm's atopic dermatitis drug is holding its own despite strong competition from Sanofi/Regeneron’s Dupixent.

Abeona Sets $3.1m Price For Rare Skin Disorder Gene Therapy

 
• By Joseph Haas

Abeona plans to offer an outcomes-based payment model for Zevaskyn, which likely will see complementary use with Krystal’s Vyjuvek in recessive dystrophic epidermolysis bullosa patients.

More from Therapy Areas

Vigil’s Iluzanebart Disappoints In Rare Neurodegenerative Disease

 
• By Jessica Merrill

The Phase II TREM2 agonist is not part of Sanofi’s planned acquisition.

Merus Raises $300m After ASCO Success

 
• By Andrew McConaghie

The company is raising the money to fuel development of its head and neck cancer candidate, petosemtamab, on the back of promising early data. Some analysts are stopping short of declaring it the winner against a rival product from Bicara, however.

Bayer Boosted By Third FDA Approval For Nubeqa

 
• By Kevin Grogan

US green light will further expand sales of the prostate cancer blockbuster.